MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

INCY · NASDAQ-GS

Incyte Corp.

Health Care · Biotechnology: Commercial Physical & Biological Resarch

Reference price$129.93As of Jul 28, 2026
Market capitalization$25.95B
52-week range$69.70–$120.71
S&P 500 portfolio weight0.03%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$99.00-23.8% vs. reference
Average$120.24-7.5% vs. reference
High$145.00+11.6% vs. reference
9 Buy9 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportNot availableJun 2026
Consensus EPS$1.767 estimates
Expected range$1.37–$2.59Low to high EPS
Dec 2026$6.90Street EPS consensus
Dec 2027$7.97Street EPS consensus
Dec 2028$10.09Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+21.2% YoY$5.14B$4.24B
Operating income$1.51B$0.06B
Net income$1.29B$0.03B
Operating cash flow$1.41B$0.34B
Capital expenditures($0.06B)($0.09B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised

RTTNews

Incyte Q2 Revenue Jumps 38%, Raises FY26 Sales Guidance

Zacks

Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.